secwatch / observer
8-K filed June 17, 2026, 4:15 PM ET ticker HEPA CIK 0001583771
other material confidence high sentiment neutral materiality 0.15

Hepion shareholders approve 40x increase in equity plan shares to 8M at annual meeting

Hepion Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. at the 2026-06-17 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
To approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. Votes For Votes Against Votes Abstained Broker Non-Vote 13,442,072 208,879 1,751 4,816,704
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. at the 2026-06-17 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 18,128,998 116,985 223,423 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Hepion Pharmaceuticals, Inc. shareholders approved Election of five director nominees: Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore at the 2026-06-17 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-17
Exact text from the filing
To elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore. Name Votes For Withhold Broker Non-Vote Gary Stetz 13,498,755 153,947 4,816,704 Vincent LoPriore 13,492,507 160,195 4,816,704 Michael Purcell 13,186,912 465,790 4,816,704 Sireesh Appajosyula 13,503,469 149,233 4,816,704 Chase LoPriore 13,492,110 160,592 4,816,704
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-26-029085
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.